Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...
Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...
3h
Zacks.com on MSNPCRX Doses First Patient in Phase II PCRX-201 Gene Therapy StudyPacira BioSciences PCRX announced that it has dosed the first patient in a mid-stage study of pipeline candidate PCRX-201 ...
Gene therapy companies have faced numerous setbacks over the last few years. What will it take for gene therapies to fulfill ...
Artis BioSolutions joins a host of startups trying to improve development and manufacturing capacity for cutting-edge gene ...
Explore more
Here is our list of the 11 Best Gene Therapy Stocks to Buy According to Analysts.
1d
GlobalData on MSNAtsena closes $150m in Series C round to progress gene therapyBain Capital’s Life Sciences team led the funding round, with contributions from new investor Wellington Management.
Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to ...
The $150 million will also go toward Atsena’s preclinical pipeline and expand the use of the biotech’s spreading AAV.SPR ...
Maria Lowe, Ph.D., associate vice president of Pharmaceutical Intelligence at Institute for Clinical and Economic Review ...
Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results